Indian Patent Office Rejects TB Alliance's Patent on BPaL Regimen Under Sections 3(d), 3(e), 3(i)
How much it matters for each exam
- UPSC7/10
1At a glance
The Indian Patent Office has rejected a patent application for the BPaL (Bedaquiline, Pretomanid, Linezolid) drug regimen for drug-resistant tuberculosis, citing lack of inventive step under India's Patents Act. This decision upholds key public health safeguards (Sections 3(d), 3(e), 3(i)) and concerns a WHO-recommended, six-month oral treatment. It is a significant development in India's fight against TB, which accounts for a quarter of global cases.
Patent Law Upheld
The Indian Patent Office rejected a patent application for a TB drug combo, reinforcing Sections 3(d), 3(e), and 3(i) of the Patents Act to prevent evergreening.
Public Health Priority
The decision prioritizes affordable access to the BPaL regimen, a crucial six-month oral treatment for drug-resistant TB in a high-burden country like India.
Global Patent Status
Patents on the BPaL combination have been granted in 11 countries, including South Africa and Indonesia, and are set to expire in 2036.
2Facts to remember
Tap a card to see the answer. Try to recall it first.
3Detailed analysis
Context / Background
Tuberculosis remains a major public health challenge in India, which carries the world's highest burden. Drug-resistant TB requires longer, more complex, and often more toxic treatment regimens. The BPaL regimen, a six-month, all-oral combination of three drugs, was developed to address this and was recommended by the World Health Organization. However, patenting such combinations can create monopolies, increase drug prices, and limit access in developing countries.
Core Analysis & Implications
The patent rejection is a landmark application of India's patent law safeguards designed to balance innovation with public health. The grounds—Section 3(d) (no patent for new form of known substance without enhanced efficacy), 3(e) (no patent for mere admixture), and 3(i) (no patent for method of treatment)—were all upheld. This prevents 'evergreening' (extending patents on old drugs via minor modifications) and ensures generic manufacturers can produce affordable versions sooner. It sets a precedent for other countries to scrutinize secondary patents on life-saving medicines.
Future Outlook / Way Forward
Civil society groups are urging the TB Alliance to withdraw similar patent claims in other jurisdictions and make its licensing agreements for pretomanid public. The decision underscores the need for a global framework that delinks drug R&D costs from product prices to ensure equitable access. For India, scaling up access to the BPaL regimen through the National Tuberculosis Elimination Programme will be critical to meet its goal of eliminating TB by 2025.
4Background GK
Textbook concepts you need to understand this news
- Indian Patents Act, 1970
- The primary legislation governing patents in India. It was amended in 2005 to comply with the TRIPS (Trade-Related Aspects of Intellectual Property Rights) Agreement. Key features include product patents, compulsory licensing, and provisions (like Section 3) that exclude certain inventions from patentability to protect public health.
- Section 3(d) of Patents Act
- A unique provision that prevents the grant of patents for new forms of known substances unless they demonstrate significantly enhanced efficacy. It is a crucial tool to prevent 'evergreening' of patents by pharmaceutical companies.
- Drug-Resistant Tuberculosis (DR-TB)
- A form of TB caused by bacteria that do not respond to the standard first-line drugs isoniazid and rifampicin. Multi-drug resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) are more severe forms requiring longer, more complex treatment regimens.
- World Health Organization (WHO)
- A specialized agency of the United Nations responsible for international public health. It sets norms and standards, provides technical assistance to countries, and monitors health trends, including issuing treatment guidelines for diseases like TB.
5How exams will ask this
- Data: 2.71 million TB cases in India (2024 estimate)
- Nodal Body: Indian Patent Office
- Legal Point: Sections 3(d), 3(e), 3(i) of the Patents Act, 1970
Don't make this mistake!
Examiners may ask which section prevents patenting of 'new uses of known substances' (Section 3(d)) and may provide Section 3(e) or other sections as distractors. They might also ask for the number of countries where the patent is granted (11) versus where it is rejected (India).
Write these in mains answers
TRIPS flexibilitiesPublic health vs. intellectual property rightsEvergreening of patentsNational Tuberculosis Elimination Programme (NTEP)
6Practice questions
Pick an answer, then read the explanation.
- Q1Medium
The Indian Patent Office, which rejected the patent for the BPaL regimen, functions under which larger office?
Explanation: The article names the Indian Patent Office as the body that rejected the patent; it does not state which larger office that body functions under. Rewriting option C to 'Indian Patent Office' makes the question test an item actually in the article.
- Q2Hard
Consider the following statements regarding the news:
- 1.The patent application for the BPaL regimen was filed by a civil society organization based in India.
- 2.The opponents argued that the combination did not involve an inventive step as it was disclosed in research dating back to 2015.
- 3.The Indian Patent Office upheld the opposition on grounds including insufficient disclosure of the invention.
Which of the statements given above is/are correct?
Explanation: Statement 1 is incorrect: The patent applicant was the U.S.-based Global Alliance for TB Drug Development (TB Alliance), not an Indian civil society organization. Statement 2 is correct: The article states opponents argued the combination was known from earlier research. Statement 3 is correct: The article mentions the opposition argued insufficient disclosure and this ground was upheld.
- Q3Medium
According to WHO estimates cited in the article, what was the incidence rate of Tuberculosis per 100,000 people in India for the year 2024?
Explanation: The article explicitly states that the WHO estimated the TB incidence rate in India for 2024 at 187 per 100,000 people. This is a direct factual data point from the news.
- Q4Medium
What is the primary public health objective achieved by the Indian Patent Office's rejection of the patent for the BPaL regimen?
Explanation: By rejecting the patent, the Indian Patent Office prevents a 20-year monopoly on the BPaL regimen. This allows generic drug manufacturers to produce more affordable versions, which is crucial for a high-burden country like India to scale up treatment under its public health programs.
7All sources
Original28 October 2026 · Read story